Attractive valuation despite negative revisions

Strong beat and outlook, but already priced in

Better PTP from non-reccuring items

Strong beat from price increases impact

Heads-up for report 11 July

Nordic non-life Q2e: A double tailwind

FX tailwind drives revisions

Steadily improving its operation

Recovery continues, but reflected in valuation

Change of commander from 1 Oct

Analyst Day: On track for '27 targets, but cautious on AI

Nordic non-life insurance – Q1 reporting wrap

Insurance trip: 16 insurers in three days

Non-life have price increases > inflation in all markets, most in Norway. Life insurance growth with rapid growth & dividend payments. Prefer ALMB, Sampo, Solid, Tryg among non-life; STB for life

Guidance and synergies lifted

Better than expected from both UW and financials

Heads-up for Q1-report, 7 May

Huge improvements priced in

Gjensidige Forskring ASA: 1 director

A director at Gjensidige Forskring ASA bought 1,000 shares at 236.000NOK and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

Gjensidige Forsikring (Hold, TP: NOK235.00) - Profitable growth ahead

On the back of repricing measures, mild winter weather, and a solid investment result, Gjensidige reported Q1 PTP of NOK1,719m, up ~60% YOY. Although we expect continued solid growth momentum on further price hikes of upwards of 19.5% in Private, the profitability focus is leading to some churn among Commercial clients. In sum, we have cut our 2026–2027e EPS by 1–2%, and reiterate our HOLD and NOK235 target price.

Financials beat just outweigh UW miss

Adj. PTP -13%/-17% vs IR and ABGSCe (higher large losses). Even more repricing could make consensus estimates unchanged. Stock valuation high, hence stock down 1-4% from the UW miss